Q5120 Pegfilgratim-bmez - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Pegfilgratim-bmez

Brand Name:

Ziextenzo

Strength:

0.5mg

HCPCS:

Q5120

SEER*Rx Category:

Ancillary Therapy

Major Drug Class:

Immunostimulant

Minor Drug Class:

Granulocyte Colony Stimulating Factor

Oral (Y/N):

No

FDA Approval Year:

2019

FDA Discontinuation Year:

CMS Effective Date:

July 1, 2020

CMS Discontinuation Date:

Status:

In Use